SION (Sionna Therapeutics) Net Income (Continuing Operations): $-97.38 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SION Sionna Therapeutics Inc SION
12 GF Score
Price $6.54
! 2 Warning Signs
View Full Analysis

What is Sionna Therapeutics Net Income (Continuing Operations)?

Sionna Therapeutics SION +4.64% 12 Net Income (Continuing Operations) is $-97.38 Mil as of Jun. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Sionna Therapeutics's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-29.89 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-97.38 Mil.

Sionna Therapeutics  (NAS:SION) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Sionna Therapeutics Net Income (Continuing Operations) Related Terms

Sionna Therapeutics Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Net Income (Continuing Operations) Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
-40.24 -47.26 -61.69 -75.27

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.07 -20.28 -20.44 -26.78 -29.89
SION
12GF Score
Sionna Therapeutics Inc SION
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-97.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-97.38 Mil mean?
Sionna Therapeutics (SION) has a Net Income (Continuing Operations) of $-97.38 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Sionna Therapeutics and its competitors.
Is Sionna Therapeutics' Net Income (Continuing Operations) too high?
Sionna Therapeutics' current Net Income (Continuing Operations) is $-97.38 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Net Income (Continuing Operations) compare to HRMY and VRDN?
Sionna Therapeutics' Net Income (Continuing Operations) of $-97.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Sionna Therapeutics and its competitors. Sionna Therapeutics's current Net Income (Continuing Operations) is $-97.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Net Income (Continuing Operations) of $-97.38 Mil. The current Net Income (Continuing Operations) is $-97.38 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Net Income (Continuing Operations) is $-97.38 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.54
Price